Literature DB >> 25863215

A Thermo-Sensitive Delivery Platform for Topical Administration of Inflammatory Bowel Disease Therapies.

Sidhartha R Sinha1, Linh P Nguyen2, Mohammed Inayathullah3, Andrey Malkovskiy3, Frezghi Habte4, Jayakumar Rajadas5, Aida Habtezion6.   

Abstract

Systemic therapies for inflammatory bowel disease are associated with an increased risk of infections and malignancies. Topical therapies reduce systemic exposure, but can be difficult to retain or have limited proximal distribution. To mitigate these issues, we developed a thermo-sensitive platform, using a polymer-based system that is liquid at room temperature but turns into a viscous gel on reaching body temperature. After rectal administration to mice with dextran sulfate sodium-induced colitis, the platform carrying budesonide or mesalamine becomes more viscoelastic near body temperature. Mice given the drug-containing platform gained more weight and had reduced histologic and biologic features of colitis than mice given the platform alone or liquid drugs via enema. Image analysis showed that enemas delivered with and without the platform reached similar distances in the colons of mice, but greater colonic retention was achieved by using the platform.
Copyright © 2015 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Drug Delivery; Mouse Model of IBD; TDDP; Technology

Mesh:

Substances:

Year:  2015        PMID: 25863215      PMCID: PMC4509789          DOI: 10.1053/j.gastro.2015.04.002

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  14 in total

1.  European evidence based consensus on the diagnosis and management of Crohn's disease: current management.

Authors:  S P L Travis; E F Stange; M Lémann; T Oresland; Y Chowers; A Forbes; G D'Haens; G Kitis; A Cortot; C Prantera; P Marteau; J-F Colombel; P Gionchetti; Y Bouhnik; E Tiret; J Kroesen; M Starlinger; N J Mortensen
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

2.  Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee.

Authors:  Asher Kornbluth; David B Sachar
Journal:  Am J Gastroenterol       Date:  2010-01-12       Impact factor: 10.864

3.  Chemically induced mouse models of intestinal inflammation.

Authors:  Stefan Wirtz; Clemens Neufert; Benno Weigmann; Markus F Neurath
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

4.  A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults.

Authors:  L Kam; H Cohen; C Dooley; P Rubin; J Orchard
Journal:  Am J Gastroenterol       Date:  1996-07       Impact factor: 10.864

5.  Medical treatment of ulcerative colitis.

Authors:  Uma Mahadevan
Journal:  Clin Colon Rectal Surg       Date:  2004-02

Review 6.  5-ASA in ulcerative colitis: improving treatment compliance.

Authors:  Cosimo Prantera; Marina Rizzi
Journal:  World J Gastroenterol       Date:  2009-09-21       Impact factor: 5.742

7.  Effect of short-term topical corticosteroid treatment on mucosal enzyme systems in patients with distal inflammatory bowel disease.

Authors:  C Scheurlen; H Allgayer; M Hardt; W Kruis
Journal:  Hepatogastroenterology       Date:  1998 Sep-Oct

8.  A murine model of chronic inflammation-induced intestinal fibrosis down-regulated by antisense NF-kappa B.

Authors:  Ian C Lawrance; Feng Wu; André Z A Leite; Joseph Willis; Gail A West; Claudio Fiocchi; Shukti Chakravarti
Journal:  Gastroenterology       Date:  2003-12       Impact factor: 22.682

Review 9.  T cell transfer model of chronic colitis: concepts, considerations, and tricks of the trade.

Authors:  Dmitry V Ostanin; Jianxiong Bao; Iurii Koboziev; Laura Gray; Sherry A Robinson-Jackson; Melissa Kosloski-Davidson; V Hugh Price; Matthew B Grisham
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-11-25       Impact factor: 4.052

10.  Budesonide inhibits T cell-initiated epithelial pathophysiology in an in vitro model of inflammation.

Authors:  D M McKay; R Brattsand; E Wieslander; M Fung; K Croitoru; M H Perdue
Journal:  J Pharmacol Exp Ther       Date:  1996-04       Impact factor: 4.030

View more
  5 in total

1.  Nanoparticulate Drug Delivery Systems Targeting Inflammation for Treatment of Inflammatory Bowel Disease.

Authors:  Sufeng Zhang; Robert Langer; Giovanni Traverso
Journal:  Nano Today       Date:  2017-10-09       Impact factor: 20.722

2.  The Antioxidant Procyanidin Reduces Reactive Oxygen Species Signaling in Macrophages and Ameliorates Experimental Colitis in Mice.

Authors:  Lu Chen; Qian You; Liang Hu; Jian Gao; Qianqian Meng; Wentao Liu; Xuefeng Wu; Qiang Xu
Journal:  Front Immunol       Date:  2018-01-05       Impact factor: 7.561

3.  Ascorbyl Palmitate Hydrogel for Local, Intestinal Delivery of Macromolecules.

Authors:  Jinyi Zhai; Julia Mantaj; Driton Vllasaliu
Journal:  Pharmaceutics       Date:  2018-10-15       Impact factor: 6.321

Review 4.  Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives.

Authors:  Chunhua Yang; Didier Merlin
Journal:  Int J Nanomedicine       Date:  2019-11-13

5.  Research-Based Product Innovation to Address Critical Unmet Needs of Patients with Inflammatory Bowel Diseases.

Authors:  Gerard Honig; Paul B Larkin; Caren Heller; Andrés Hurtado-Lorenzo
Journal:  Inflamm Bowel Dis       Date:  2021-11-15       Impact factor: 5.325

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.